109 related articles for article (PubMed ID: 28790261)
1. [Third- and Fourth-Line Chemotherapies including Paclitaxel and Bevacizumab for Metastatic Breast Cancer].
Sakamoto M; Nio Y; Imai S; Uesugi K; Tamaoki M; Tamaoki M
Gan To Kagaku Ryoho; 2017 Jul; 44(7):579-584. PubMed ID: 28790261
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.
Yamamoto Y; Yamashiro H; Schneeweiss A; Müller V; Gluz O; Klare P; Aktas B; Magdolna D; Büdi L; Pikó B; Mangel L; Toi M; Morita S; Ohno S
Breast Cancer; 2023 Jan; 30(1):88-100. PubMed ID: 36057014
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
[TBL] [Abstract][Full Text] [Related]
5. Locally advanced breast cancer with bleeding - two cases effectively treated with bevacizumab plus weekly paclitaxel.
Ishizuna K; Ninomiya J; Ogawa T; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y
Gan To Kagaku Ryoho; 2014 May; 41(5):637-40. PubMed ID: 24917012
[TBL] [Abstract][Full Text] [Related]
6. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
7. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
8. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
Schwartzberg LS; Badarinath S; Keaton MR; Childs BH
Clin Breast Cancer; 2014 Jun; 14(3):161-8. PubMed ID: 24566467
[TBL] [Abstract][Full Text] [Related]
9. [The combined effect of paclitaxel and toremifene therapy for metastatic breast cancer].
Sakurai K; Matsuo S; Enomoto K; Amano S; Shiono M
Gan To Kagaku Ryoho; 2009 Nov; 36(12):1994-6. PubMed ID: 20037302
[TBL] [Abstract][Full Text] [Related]
10. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Drooger JC; van Tinteren H; de Groot SM; Ten Tije AJ; de Graaf H; Portielje JE; Jager A; Honkoop A; Linn SC; Kroep JR; Erdkamp FL; Hamberg P; Imholz AL; van Rossum-Schornagel QC; Heijns JB; van Leeuwen-Stok AE; Sleijfer S
Cancer; 2016 Oct; 122(19):2961-70. PubMed ID: 27315546
[TBL] [Abstract][Full Text] [Related]
12. First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
Dank M; Budi L; Piko B; Mangel L; Erfan J; Cseh J; Ruzsa A; Landherr L
Anticancer Res; 2014 Mar; 34(3):1275-80. PubMed ID: 24596372
[TBL] [Abstract][Full Text] [Related]
13. First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
Dieras V; Pop S; Berger F; Dujaric ME; Beuzeboc P; Escalup L; Bidard FC; Cottu PH; LE Tourneau C; Piperno-Neumann S; Laurence V; Robain M; Asselain B; Pierga JY
Anticancer Res; 2017 Mar; 37(3):1403-1407. PubMed ID: 28314310
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Yardley DA; Bosserman LD; O'Shaughnessy JA; Harwin WN; Morgan SK; Priego VM; Peacock NW; Bass JD; Burris HA; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(1):89-97. PubMed ID: 26456573
[TBL] [Abstract][Full Text] [Related]
15. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.
Li T; Wang B; Wang Z; Ragaz J; Zhang J; Sun S; Cao J; Lv F; Wang L; Zhang S; Ni C; Wu Z; Xie J; Hu X
PLoS One; 2015; 10(7):e0133133. PubMed ID: 26186012
[TBL] [Abstract][Full Text] [Related]
17. [The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
Sakurai K; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2246-8. PubMed ID: 21224536
[TBL] [Abstract][Full Text] [Related]
18. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
[TBL] [Abstract][Full Text] [Related]
19. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
Gamucci T; Mentuccia L; Natoli C; Sperduti I; Cassano A; Michelotti A; Di Lauro L; Sergi D; Fabi A; Sarobba MG; Marchetti P; Barba M; Magnolfi E; Maugeri-Saccà M; Rossi E; Sini V; Grassadonia A; Pellegrini D; Astone A; Nisticò C; Angelini F; Vaccaro A; Pellegrino A; De Angelis C; Palleschi M; Moscetti L; Bertolini I; Buglioni S; Giordano A; Pizzuti L; Vici P
J Cell Physiol; 2017 Jun; 232(6):1571-1578. PubMed ID: 27861874
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer.
Yoshinami T; Yagi T; Okuno J; Kittaka N; Ishitobi M; Sugimoto N; Nakayama T; Tamaki Y; Imamura F
Breast Cancer; 2017 Jan; 24(1):147-151. PubMed ID: 27010394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
